Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

DE (n=1) and 12 percent of

patients receiving adefovir (n=5) experienced a serious adverse event.

-- No deaths were observed in either treatment group.

-- No patients in the BARACLUDE arm and one patient in the adefovir arm

experienced an ALT flare (defined as ALT greater than two times

baseline and greater than 10 times the upper limit of normal).

About the Study

The E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infections, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. The secondary endpoints included the mean change in viral load from baseline through week 96, the proportion of patients in each treatment group who achieved ALT normalization, HBeAg loss and HBe seroconversion, and safety.

Sixty-nine patients were randomized in the study and of these, 65 completed the first 12 weeks. Patients in this study received either 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32) for a minimum of 52 weeks. Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL.

According to study protocol, patients who achieved a treatment response at 52 weeks discontinued treatment and entered a follow-up monitoring phase. Three BARACLUDE-treated patients and four adefovir-treated patients met this criterion and entered the follow-up monitoring phase lasting up to 48 weeks. Patients who did not achieve a treatment response at 52 weeks continued on study
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The ... in Boston, MA on May 29, ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may access Mr. ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... SAINT PAUL, Minn. , May 23, 2013 /PRNewswire/ ... Angeion Corporation), a global medical technology company, today scheduled ... the second quarter of fiscal year 2013, ended April ... ET on Thursday, May 30, 2013. The Company will ... year 2013 after the markets close on Thursday, May ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... Reportlinker.com announces that a new ... its catalogue: Neurosurgical ... Russia, India, China, South Africa) to ... Neurosurgical Products Market ...
... 2011 Kowa Pharmaceuticals America, Inc. ... LLY ) today released new study results that ... (pitavastatin) 4 mg in healthy volunteers taking the ... combination drug for the treatment of HIV infection.(1) ...
Cached Medicine Technology:Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Neurosurgical Products Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 2New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 3New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 4New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 5New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 6New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 7
(Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
(Date:5/25/2013)... 2013 Absolute Surgical Specialists, serving Sun City ... NALA’s businesses throughout the country participating in Shop Local for ... the nationwide event as he understands what military families go ... Army. He said, “I wanted to give something back, as ... I live here too.” , Shop Local for a Cause ...
(Date:5/25/2013)... Pradaxa lawsuits filed on ... internal bleeding while using the blood thinner continue to mount ... District of Illinois, Bernstein Liebhard LLP reports. According to ... claims had been filed in the litigation as ... reported by the Court on May 15th. ( In Re: ...
(Date:5/25/2013)... May 25, 2013 By working diligently ... declared the integration of the 2012 Lamborghini Aventador into ... the latest entrant in the list of vehicles lined ... vehicle is all set to thrill automobile lovers in ... power and spectacular looks, the 2012 Lamborghini Aventador comes ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... ... Replikin Count* of H1N1 Lethality Gene , ... Boston (PRWeb) June 11, 2009-- As the World Health Organization raised its pandemic alert to phase ... latest peptide genomic data for the H1N1 influenza virus shows that the current global ...
... Closer to Enactment , , , WASHINGTON, June ... M.D., American Medical Association President: , , (Logo: ... of legislation that will for the first time allow the ... Passage of this historic legislation by both the House and ...
... June 11 Anderson Hospital administration ... Healthcare Solutions congratulate the ED Patient ... of the coveted Pinnacle Award. The ED Patient Throughput Team, ... chosen from a group of three finalists to receive the ...
... HLS ) today announced it will host an investor conference ... discuss its results for the second quarter of 2009. , ... 406-5369 and giving the pass code 14033624. International callers should dial ... 10 minutes before the start of the call to ensure you ...
... Legislation to let FDA regulate tobacco manufacturing and marketing ... -- The U.S. Senate,s historic vote late Thursday to ... tobacco products brought cheers from health organizations across the ... to Big Tobacco,s despicable marketing practices that are designed ...
... Inc. (NYSE: EAT ), announced its support and ... in bringing the restaurant industry, government and public health interests ... its nutritional information online for a number of years, and ... information so they can make informed dining decisions. , ...
Cached Medicine News:Health News:Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 2Health News:Lethality of H1N1 Influenza Virus Increasing According to Latest Replikin Analysis of Virus Peptide Genomic Data 3Health News:AMA Cheers Senate Passage of Historic Tobacco Regulation Bill 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 3Health News:HealthSouth Announces Date of 2009 Second Quarter Earnings Conference Call 2Health News:Health Organizations Cheer Senate Vote on Tobacco Control 2Health News:Health Organizations Cheer Senate Vote on Tobacco Control 3Health News:Brinker International Announces Support of Senate's Agreement on Uniform Nutrition Disclosure 2
Microwell-EIA for the detection of Insulin Autoantibody....
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... integrated color touch screen shows you ... sensor cassette it is ready-to-go in ... bottle assures accurate calibration prior to ... comes with a removable, rechargeable battery, ...
... Roche OMNI S is the ... completes and extends the Roche ... of Care applications. The modular ... comprehensive parameter menu as well ...
Medicine Products: